To summarize, NK1 receptor antagonists administered either orally or intravenously failed to demonstrate superiority to placebo in either acute or preventive migraine therapy.
To summarize, NK1 receptor antagonists administered either orallyor intravenously failed to demonstrate superiority to placebo in eitheracute or preventive migraine therapy.